• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性血管性水肿:在急诊科如何处理?

Hereditary angioedema: how to approach it at the emergency department?

机构信息

Escola Superior de Ciências, Santa Casa de Misericórdia de Vitória, Vitória, ES, Brazil.

Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.

出版信息

Einstein (Sao Paulo). 2021 Apr 9;19:eRW5498. doi: 10.31744/einstein_journal/2021RW5498. eCollection 2021.

DOI:10.31744/einstein_journal/2021RW5498
PMID:33852678
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8020838/
Abstract

Angioedema attacks are common causes of emergency care, and due to the potential for severity, it is important that professionals who work in these services know their causes and management. The mechanisms involved in angioedema without urticaria may be histamine- or bradykinin-mediated. The most common causes of histamine-mediated angioedema are foods, medications, insect sting and idiopathic. When the mediator is bradykinin, the triggers are angiotensin-converting enzyme inhibitors and factors related to acquired angioedema with deficiency of C1-inhibitor or hereditary angioedema, which are less common, but very important because of the possibility of fatal outcome. Hereditary angioedema is a rare disease characterized by attacks of edema that affect the subcutaneous tissue and mucous membranes of various organs, manifesting mainly by angioedema and abdominal pain. This type of angioedema does not respond to the usual treatment with epinephrine, antihistamines and corticosteroids. Thus, if not identified and treated appropriately, these patients have an estimated risk of mortality from laryngeal edema of 25% to 40%. Hereditary angioedema treatment has changed dramatically in recent years with the development of new and efficient drugs for attack management: plasma-derived C1 inhibitor, recombinant human C1-inhibitor, bradykinin B2 receptor antagonist (icatibant), and the kallikrein inhibitor (ecallantide). In Brazil, plasma-derived C1 inhibitor and icatibant have already been approved for use. Proper management of these patients in the emergency department avoids unnecessary surgery and, especially, fatal outcomes.

摘要

血管性水肿发作是急诊常见的原因,由于其严重程度的潜在风险,在这些服务机构工作的专业人员了解其病因和管理非常重要。无荨麻疹的血管性水肿的发病机制可能与组胺或缓激肽有关。组胺介导的血管性水肿最常见的原因是食物、药物、昆虫叮咬和特发性。当介质为缓激肽时,触发因素是血管紧张素转换酶抑制剂和与获得性血管性水肿伴 C1 抑制剂缺乏或遗传性血管性水肿相关的因素,这些因素较少见,但非常重要,因为可能导致致命后果。遗传性血管性水肿是一种罕见的疾病,其特征为影响皮下组织和各种器官黏膜的水肿发作,主要表现为血管性水肿和腹痛。这种类型的血管性水肿对通常使用肾上腺素、抗组胺药和皮质类固醇治疗没有反应。因此,如果不能识别并适当治疗,这些患者发生喉水肿的死亡率估计为 25%至 40%。近年来,随着新的、有效的治疗发作药物的发展,遗传性血管性水肿的治疗发生了巨大变化:血浆衍生的 C1 抑制剂、重组人 C1 抑制剂、缓激肽 B2 受体拮抗剂(依卡替班)和激肽释放酶抑制剂(艾卡替班)。在巴西,已经批准使用血浆衍生的 C1 抑制剂和依卡替班。在急诊科对这些患者进行适当的管理可以避免不必要的手术,特别是致命的后果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/8fd9eee87726/2317-6385-eins-19-eRW5498-gf04-pt.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/5774a770fb26/2317-6385-eins-19-eRW5498-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/dd447109f41b/2317-6385-eins-19-eRW5498-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/918cb7dd3212/2317-6385-eins-19-eRW5498-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/7f568401edbb/2317-6385-eins-19-eRW5498-gf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/988e9bed6823/2317-6385-eins-19-eRW5498-gf01-pt.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/375d3d5817b2/2317-6385-eins-19-eRW5498-gf02-pt.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/59bb6f25b4a5/2317-6385-eins-19-eRW5498-gf03-pt.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/8fd9eee87726/2317-6385-eins-19-eRW5498-gf04-pt.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/5774a770fb26/2317-6385-eins-19-eRW5498-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/dd447109f41b/2317-6385-eins-19-eRW5498-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/918cb7dd3212/2317-6385-eins-19-eRW5498-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/7f568401edbb/2317-6385-eins-19-eRW5498-gf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/988e9bed6823/2317-6385-eins-19-eRW5498-gf01-pt.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/375d3d5817b2/2317-6385-eins-19-eRW5498-gf02-pt.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/59bb6f25b4a5/2317-6385-eins-19-eRW5498-gf03-pt.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aea/8020838/8fd9eee87726/2317-6385-eins-19-eRW5498-gf04-pt.jpg

相似文献

1
Hereditary angioedema: how to approach it at the emergency department?遗传性血管性水肿:在急诊科如何处理?
Einstein (Sao Paulo). 2021 Apr 9;19:eRW5498. doi: 10.31744/einstein_journal/2021RW5498. eCollection 2021.
2
Novelties in the Diagnosis and Treatment of Angioedema.血管性水肿的诊断和治疗新进展。
J Investig Allergol Clin Immunol. 2016;26(4):212-21; quiz two pages after page 221. doi: 10.18176/jiaci.0087.
3
Managing Chronic Urticaria and Recurrent Angioedema Differently with Advancing Age.随着年龄的增长,慢性荨麻疹和复发性血管性水肿的管理方式也不同。
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2186-2194. doi: 10.1016/j.jaip.2021.03.034. Epub 2021 Apr 2.
4
Recognition and Differential Diagnosis of Hereditary Angioedema in the Emergency Department.急诊科遗传性血管性水肿的识别与鉴别诊断。
J Emerg Med. 2021 Jan;60(1):35-43. doi: 10.1016/j.jemermed.2020.09.044. Epub 2020 Nov 17.
5
Bradykinin-mediated angioedema.缓激肽介导的血管性水肿。
Pol Arch Med Wewn. 2016;126(1-2):76-85. doi: 10.20452/pamw.3273.
6
Bradykinin-mediated diseases.缓激肽介导的疾病
Chem Immunol Allergy. 2014;100:140-7. doi: 10.1159/000358619. Epub 2014 May 22.
7
Angioedema without wheals: a clinical update.无风团性血管性水肿:临床更新。
Balkan Med J. 2021 Mar;38(2):73-81. doi: 10.5152/balkanmedj.2021.20060.
8
Isolated Intestinal Angioedema in the Emergency Department.急诊科的孤立性肠道血管性水肿
J Emerg Med. 2016 Apr;50(4):660-2. doi: 10.1016/j.jemermed.2015.09.049. Epub 2016 Feb 15.
9
Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor-Induced Angioedema.用于治疗严重或危及生命的血管紧张素转换酶抑制剂诱导的血管性水肿的药物的超说明书用药
Ann Pharmacother. 2016 Jan;50(1):47-59. doi: 10.1177/1060028015607037. Epub 2015 Sep 28.
10
Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema.血管性水肿的多面性:重点关注遗传性血管性水肿腹部表现的诊断和管理。
Eur J Gastroenterol Hepatol. 2012 Apr;24(4):353-61. doi: 10.1097/MEG.0b013e3283517998.

引用本文的文献

1
Impact of Dental Procedures on Hereditary Angioedema Attacks: An Exploratory Observational Study.牙科手术对遗传性血管性水肿发作的影响:一项探索性观察研究。
Oral Health Prev Dent. 2025 Mar 14;23:173-182. doi: 10.3290/j.ohpd.c_1907.
2
Hereditary Angioedema.遗传性血管性水肿
Cureus. 2023 Jul 18;15(7):e42088. doi: 10.7759/cureus.42088. eCollection 2023 Jul.
3
The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.国际血管性水肿学会(WAO)/欧洲变态反应和临床免疫学会(EAACI)遗传性血管性水肿管理指南——2021年修订与更新

本文引用的文献

1
Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.用于预防遗传性血管性水肿(HAE)的注射用拉那度单抗:设计、研发及治疗地位
Drug Des Devel Ther. 2019 Oct 22;13:3635-3646. doi: 10.2147/DDDT.S192475. eCollection 2019.
2
Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin.遗传性血管性水肿与一种新型激肽原1基因突变共分离,该突变改变了缓激肽的N端切割位点。
Allergy. 2019 Dec;74(12):2479-2481. doi: 10.1111/all.13869. Epub 2019 Jun 7.
3
Assessment on hereditary angioedema burden of illness in Brazil: A patient perspective.
World Allergy Organ J. 2022 Apr 7;15(3):100627. doi: 10.1016/j.waojou.2022.100627. eCollection 2022 Mar.
巴西遗传性血管性水肿疾病负担评估:患者视角。
Allergy Asthma Proc. 2019 May 1;40(3):193-197. doi: 10.2500/aap.2019.40.4207.
4
Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy.妊娠期采用艾替班特和重组 C1 抑制剂治疗遗传性血管性水肿发作。
J Clin Immunol. 2018 Oct;38(7):810-815. doi: 10.1007/s10875-018-0553-4. Epub 2018 Oct 2.
5
Angioedema and emergency medicine: From pathophysiology to diagnosis and treatment.血管性水肿与急诊医学:从病理生理学到诊断与治疗。
Eur J Intern Med. 2019 Jan;59:8-13. doi: 10.1016/j.ejim.2018.09.004. Epub 2018 Sep 13.
6
Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies.缓激肽介导的血管性水肿的流行病学:对流行病学研究的系统调查。
Orphanet J Rare Dis. 2018 May 4;13(1):73. doi: 10.1186/s13023-018-0815-5.
7
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.欧洲过敏研究学会/过敏标准委员会/欧洲皮肤病学会/世界变态反应组织荨麻疹指南:定义、分类、诊断和管理。
Allergy. 2018 Jul;73(7):1393-1414. doi: 10.1111/all.13397.
8
An ABC of the Warning Signs of Hereditary Angioedema.遗传性血管性水肿警示信号ABC
Int Arch Allergy Immunol. 2017;174(1):1-6. doi: 10.1159/000479839. Epub 2017 Sep 27.
9
Hereditary angioedema with a mutation in the plasminogen gene.遗传性血管性水肿伴纤溶酶原基因突变。
Allergy. 2018 Feb;73(2):442-450. doi: 10.1111/all.13270. Epub 2017 Sep 7.
10
Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade.遗传性血管性水肿的发病机制:激肽形成级联反应的作用
Immunol Allergy Clin North Am. 2017 Aug;37(3):513-525. doi: 10.1016/j.iac.2017.04.001.